{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:25:37Z","timestamp":1790270737725,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":83,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["RS-2024-00406716"],"award-info":[{"award-number":["RS-2024-00406716"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hepatocellular carcinoma (HCC) frequently coexists with portal hypertension, significantly increasing the risk of hepatic decompensation (HD) and variceal bleeding during systemic therapy. We developed a machine learning based hepatic safety score (MHSS) using data from 2026 patients with unresectable HCC to predict clinically significant portal hypertension (CSPH) and prognosis. A random forest model was trained in a derivation cohort (n\u2009=\u20091262) and validated in an independent cohort (n\u2009=\u2009764). The MHSS demonstrated robust performance (AUROC 0.840) in CSPH and predicting HD. Stratification revealed that high MHSS patients faced significantly elevated risks of HD (HR 3.25), variceal bleeding (VB, HR 4.90), and mortality (HR 2.21). Crucially, while atezolizumab-bevacizumab offered a survival advantage in low MHSS patients, it was associated with high bleeding risk and no survival benefit in the high MHSS group compared to other regimens. A simulation of MHSS guided treatment selection demonstrated a 24% reduction in HD, a 40% reduction in VB, and a 26% reduction in mortality. In conclusion, the MHSS effectively predicts CSPH, decompensation, and survival in patients with HCC prior to systemic therapy. By enabling individualized risk stratification, the MHSS may guide personalized treatment selection between bevacizumab-containing and alternative regimens, ultimately improving patient outcomes. Clinical trial number: not applicable.<\/jats:p>","DOI":"10.1038\/s41746-026-02802-3","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:44:08Z","timestamp":1779410648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Machine learning based hepatic safety score predicts decompensation in hepatocellular carcinoma systemic therapy"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1456-1450","authenticated-orcid":false,"given":"Ji Won","family":"Han","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaejun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keungmo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwon Yong","family":"Tak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Hyun","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Sun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heechul","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hae Lim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Yeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahlim","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do Seon","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myeong Jun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Woo","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Kyu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Hyun","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pil Soo","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Won","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2802_CR1","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.3350\/cmh.2024.0824","volume":"31","author":"SY Hwang","year":"2025","unstructured":"Hwang, S. Y. et al. Hepatocellular carcinoma: Updates on epidemiology, surveillance, diagnosis and treatment. Clin. Mol. Hepatol. 31, S228\u2013S254 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"2802_CR2","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1158\/1078-0432.CCR-24-2582","volume":"31","author":"G Cabibbo","year":"2025","unstructured":"Cabibbo, G. et al. Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab or sorafenib at highest risk of death. Clin. Cancer Res. 31, 543\u2013550 (2025).","journal-title":"Clin. Cancer Res"},{"key":"2802_CR3","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1097\/HEP.0000000000001026","volume":"81","author":"C Celsa","year":"2025","unstructured":"Celsa, C. et al. Hepatic decompensation is the major driver of mortality in patients with HCC treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment. Hepatology 81, 837\u2013852, https:\/\/doi.org\/10.1097\/HEP.0000000000001026 (2025).","journal-title":"Hepatology"},{"key":"2802_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1053\/j.gastro.2007.05.024","volume":"133","author":"C Ripoll","year":"2007","unstructured":"Ripoll, C. et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology 133, 481\u2013488 (2007).","journal-title":"Gastroenterology"},{"key":"2802_CR5","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1016\/j.dld.2024.02.018","volume":"56","author":"P Sultanik","year":"2024","unstructured":"Sultanik, P. et al. Portal hypertension is associated with poorer outcome and clinical liver decompensation in patients with HCC treated with Atezolizumab-Bevacizumab. Dig. Liver Dis. 56, 1621\u20131630 (2024).","journal-title":"Dig. Liver Dis."},{"key":"2802_CR6","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.231208","volume":"309","author":"S Heo","year":"2023","unstructured":"Heo, S. et al. CT rule-in and rule-out criteria for clinically significant portal hypertension in chronic liver disease. Radiology 309, e231208 (2023).","journal-title":"Radiology"},{"key":"2802_CR7","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson, P. J. et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J. Clin. Oncol. 33, 550\u2013558 (2015).","journal-title":"J. Clin. Oncol."},{"key":"2802_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.3350\/cmh.2024.0661","volume":"31","author":"A Deshmukh","year":"2025","unstructured":"Deshmukh, A. & Maiwall, R. From invasive to intuitive: The emerging role of non-invasive models in hepatic decompensation: Editorial on \u201cCarvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306). Clin. Mol. Hepatol. 31, 577\u2013580 (2025).","journal-title":"Clin. Mol. Hepatol."},{"key":"2802_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70368","volume":"45","author":"E Ozkaya","year":"2025","unstructured":"Ozkaya, E. et al. Multiparametric MRI for diagnosing clinically significant portal hypertension and predicting liver decompensation. Liver Int 45, e70368 (2025).","journal-title":"Liver Int"},{"key":"2802_CR10","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1111\/j.1572-0241.2008.01826.x","volume":"103","author":"A Berzigotti","year":"2008","unstructured":"Berzigotti, A. et al. Noninvasive prediction of clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. Am. J. Gastroenterol. 103, 1159\u20131167 (2008).","journal-title":"Am. J. Gastroenterol."},{"key":"2802_CR11","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal, A. G. et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology 78, 1922\u20131965 (2023).","journal-title":"Hepatology"},{"key":"2802_CR12","doi-asserted-by":"publisher","first-page":"671","DOI":"10.2147\/JHC.S462701","volume":"12","author":"B Stefanini","year":"2025","unstructured":"Stefanini, B. et al. ALBI grade enables risk stratification for bleeding events and refines prognostic prediction in advanced HCC following atezolizumab and bevacizumab. J. Hepatocell. Carcinoma 12, 671\u2013683 (2025).","journal-title":"J. Hepatocell. Carcinoma"},{"key":"2802_CR13","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1111\/apt.18526","volume":"61","author":"K Park","year":"2025","unstructured":"Park, K. et al. Risk of variceal bleeding in patients receiving atezolizumab-bevacizumab treatment for hepatocellular carcinoma. Aliment Pharm. Ther. 61, 1310\u20131317 (2025).","journal-title":"Aliment Pharm. Ther."},{"key":"2802_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.639235","volume":"11","author":"C Frangakis","year":"2021","unstructured":"Frangakis, C. et al. Longitudinal analysis of the effect of repeated transarterial chemoembolization for liver cancer on portal venous pressure. Front Oncol. 11, 639235 (2021).","journal-title":"Front Oncol."},{"key":"2802_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.17998\/jlc.2023.11.21","volume":"24","author":"YG Song","year":"2024","unstructured":"Song, Y. G., Yoo, J. J., Kim, S. G. & Kim, Y. S. Complications of immunotherapy in advanced hepatocellular carcinoma. J. Liver Cancer 24, 9\u201316 (2024).","journal-title":"J. Liver Cancer"},{"key":"2802_CR16","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2147\/JHC.S520318","volume":"12","author":"YJ Chen","year":"2025","unstructured":"Chen, Y. J. et al. Primary prophylaxis for high-risk varices in patients with hepatocellular carcinoma and portal vein tumor thrombus delayed hepatic decompensation: A retrospective, propensity score matching study. J. Hepatocell. Carcinoma 12, 1057\u20131067 (2025).","journal-title":"J. Hepatocell. Carcinoma"},{"key":"2802_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.annonc.2024.02.005","volume":"35","author":"B Sangro","year":"2024","unstructured":"Sangro, B. et al. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann. Oncol. 35, 448\u2013457 (2024).","journal-title":"Ann. Oncol."},{"key":"2802_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.17998\/jlc.2025.02.03","volume":"25","author":"H Shin","year":"2025","unstructured":"Shin, H. & Yu, S. J. A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017\u20132024. J. Liver Cancer 25, 19\u201330 (2025).","journal-title":"J. Liver Cancer"},{"key":"2802_CR19","doi-asserted-by":"publisher","first-page":"262","DOI":"10.17998\/jlc.2023.07.17","volume":"23","author":"MMP Lee","year":"2023","unstructured":"Lee, M. M. P., Chan, L. L. & Chan, S. L. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma. J. Liver Cancer 23, 262\u2013271 (2023).","journal-title":"J. Liver Cancer"},{"key":"2802_CR20","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig, M. et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 76, 681\u2013693 (2022).","journal-title":"J. Hepatol."},{"key":"2802_CR21","doi-asserted-by":"crossref","unstructured":"Korean Liver Cancer, A. & National Cancer Center, K. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin. Mol. Hepatol. 28, 583\u2013705 (2022)..","DOI":"10.3350\/cmh.2022.0294"},{"key":"2802_CR22","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1158\/1078-0432.CCR-23-3978","volume":"30","author":"JW Han","year":"2024","unstructured":"Han, J. W. et al. A machine learning algorithm facilitates prognosis prediction and treatment selection for barcelona clinic liver cancer stage C hepatocellular carcinoma. Clin. Cancer Res. 30, 2812\u20132821 (2024).","journal-title":"Clin. Cancer Res"},{"key":"2802_CR23","doi-asserted-by":"publisher","first-page":"e2532353","DOI":"10.1001\/jamanetworkopen.2025.32353","volume":"8","author":"HU Kim","year":"2025","unstructured":"Kim, H. U. et al. Machine learning-based selection of resection vs transplant and survival in hepatocellular carcinoma. JAMA Netw. Open 8, e2532353 (2025).","journal-title":"JAMA Netw. Open"}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02802-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02802-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02802-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T22:33:58Z","timestamp":1786574038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-026-02802-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2802"],"URL":"https:\/\/doi.org\/10.1038\/s41746-026-02802-3","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"25 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"623"}}